Dec 06, 2022 / 11:30AM GMT
Cecilia E. Furlong - Morgan Stanley, Research Division - Equity Analyst
Great. Good morning, everyone. Thank you for joining us for the 47th NASDAQ Conference in association with Morgan Stanley. I'm Cecilia Furlong, a Medical Device Analyst here at Morgan Stanley. It's my pleasure to have Insulet with us, CEO, Jim Hollingshead; and then also Deb Gordon, IR. Thank you both for being here with us today.
James R. Hollingshead - Insulet Corporation - President, CEO & Director
Thanks, Cecilia. It's great to be here. And is this still morning or good afternoon, everybody. It's nice to see you all here. Let me just start with a couple of comments about Insulet for those of you who may not know us. Our mission is to massively simplify the lives for people with diabetes. And we're known for the Omnipod product platform.
The Omnipod is a wearable disposable tubeless insulin delivery system. We're really excited that we've just launched the fifth generation of that product, which also includes an automated insulin delivery algorithm is a product called the
Insulet Corp at Nasdaq Investor Conference Transcript
Jan 23, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers